Monte Rosa Therapeutics, INC Form 4 insider transactions

Monte Rosa Therapeutics' Principal Accounting Officer, Edmund Dunn, sold 1,039 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Monte Rosa Therapeutics' President and CEO, Markus Warmuth, reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Monte Rosa Therapeutics' Chief Scientific Officer, Sharon Townson, reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Monte Rosa Therapeutics, Inc. Director Eric A. Hughes was granted 30,700 stock options with an exercise price of $4.91, vesting by June 2026 or the next annual meeting.

Andrew N. Schiff, a Director at Monte Rosa Therapeutics, Inc., has been granted 30,700 stock options with an exercise price of $4.91 per share.

Ali Behbahani, a Director and 10% owner of Monte Rosa Therapeutics, Inc., was granted 30,700 stock options with an exercise price of $4.91, vesting by June 2026.

Anthony M. Manning, a Director at Monte Rosa Therapeutics, Inc., was granted 30,700 stock options with an exercise price of $4.91 per share.

Kimberly Blackwell, a Director at Monte Rosa Therapeutics, Inc., was granted 30,700 stock options with an exercise price of $4.91 per share, vesting over approximately one year.

Monte Rosa Therapeutics, Inc. director Christine Siu was granted 30,700 stock options with an exercise price of $4.91, aligning her interests with shareholders.

Monte Rosa Therapeutics, Inc. has reported that Director Jan Skvarka was granted 30,700 stock options with an exercise price of $4.91 per share, vesting over approximately one year.

Monte Rosa Therapeutics' Principal Accounting Officer, Edmund Dunn, sold 2,062 shares of common stock to satisfy tax withholding obligations related to restricted stock unit vesting.

Director Leo Chandra P. of Monte Rosa Therapeutics, Inc. purchased 10,000 shares of common stock at a price of $5.8383 on March 24, 2025.

Philip Nickson, Chief Business & Legal Officer of Monte Rosa Therapeutics, acquired 36,000 shares of common stock and options to purchase 161,000 shares on January 2, 2025.

Edmund Dunn, Principal Accounting Officer of Monte Rosa Therapeutics, reports acquisition of common stock and stock options.

Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, reports acquisition of shares and stock options.

Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, reports the acquisition of 30,000 shares of common stock and 135,000 stock options.

Markus Warmuth, President & CEO of Monte Rosa Therapeutics, reports the acquisition of common stock and stock options, including restricted stock units, under the company's 2021 Stock Option and Incentive Plan.

Sharon Townson, Chief Scientific Officer of Monte Rosa Therapeutics, reports acquisition of common stock and stock options.

Director Eric A. Hughes of Monte Rosa Therapeutics acquired 44,200 stock options on December 11, 2024, which vest over 36 months.

Versant Venture Capital VI, L.P. files Form 4 detailing sales and distributions of Monte Rosa Therapeutics, Inc. common stock.

Versant Venture Capital VI, L.P. sold 1,132,566 shares of Monte Rosa Therapeutics, Inc. at a weighted average price of $6.5296 on September 20, 2024.

Versant Venture Capital VI, L.P. reports the sale of Monte Rosa Therapeutics, Inc. shares over three days in September 2024.

Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics, acquired 30,000 shares of common stock through a stock option after meeting certain performance criteria.

Edmund Dunn, Principal Accounting Officer of Monte Rosa Therapeutics, sold 1,610 shares of common stock on July 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Ali Behbahani, a director at Monte Rosa Therapeutics, acquired stock options for 22,100 shares of common stock on June 12, 2024.

Director Andrew N Schiff acquired 22,100 stock options in Monte Rosa Therapeutics, Inc. on June 12, 2024.

Director Jan Skvarka acquired 22,100 stock options in Monte Rosa Therapeutics, Inc. on June 12, 2024.

Christine Siu, a director of Monte Rosa Therapeutics, acquired stock options for 22,100 shares at an exercise price of $4.16 on June 12, 2024.

Director Anthony M. Manning acquired stock options for 22,100 shares of Monte Rosa Therapeutics, Inc. (GLUE) on June 12, 2024.